NYSE and ASX-listed Resmed, a US-based sleep health technology company, has completed its acquisition of Noctrix Health, a US-based medical device company developing clinically validated wearable therapeutics for chronic neurological disorders, from Angelini Ventures in a transaction valued at US$340m.
The acquisition expands Resmed’s clinical sleep health portfolio into the adjacent treatment area of Restless Legs Syndrome (RLS).
“[The acquisition] marks an important step forward in advancing our 2030 strategy and expanding our clinical sleep health portfolio,” said Mick Farrell, chairman and CEO of Resmed.
Noctrix’s Nidra Tonic Motor Activation (TOMAC) Therapy is an FDA De Novo classified, non-invasive, non-pharmacologic treatment designed to reduce symptoms of moderate-to-severe RLS and improve sleep quality in adults who have not found sufficient relief with drug therapy.
Resmed plans to integrate Noctrix’s technology into its portfolio of connected devices and digital health solutions to help expand access, improve care pathways and enhance patient outcomes over time.
For Noctrix Health, founded in 2016, the deal brings an opportunity to scale its innovation, expand patient access, and accelerate impact for providers, patients and health systems.
“Joining Resmed will help us . . . expand access to TOMAC therapy and reach more patients with a clinically validated solution that can help meaningfully improve sleep and quality of life,” said Shri Raghunathan, president and CEO of Noctrix Health.
First exit for Angelini
Noctrix is a portfolio company of Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech. It represents Angelini’s first portfolio company exit. Angelini Ventures invested in Noctrix Health in 2024 as part of a US$40m Series C financing round, led by Sectoral Asset Management, that also featured support from Resmed, Asahi Kasei Corporation, OrbiMed, Treo Ventures and other healthcare investors.
“This marks our first successful exit, reaffirming our strategy of backing disruptive healthcare companies with the potential to address significant medical needs,” said Paolo Di Giorgio, CEO and managing director of Angelini Ventures. “We are delighted to see that the company’s technology will become integrated into Resmed’s broader connected health ecosystem, creating new opportunities to expand patient access and impact at scale.”
Noctrix represented Angelini’s sixteenth investment since its inception in October 2022.
Press release: Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio | Resmed Inc
